GlassScriptPhysician profile
Floyd L Angus
NPI 1124091137
$13,654.22
in general payments reported to CMS, 2019-2025
41 companies · $2,499 in 2025
The $2,499 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $1,093 · 2021: $1,526 · 2022: $1,851 · 2023: $2,583 · 2024: $2,558 · 2025: $2,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,540 · Education: $99.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,540.27 |
| Education | $99.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,407.98 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,423.16 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $864.83 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $826.49 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Ironwood Pharmaceuticals, INC | $636.13 | 2019-2025 | Linzess |
| Pfizer INC. | $627.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $431.29 | 2019-2024 | Dificid |
| Celgene Corporation | $307.78 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $304.19 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $301.53 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $271.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $259.35 | 2022-2024 | Sucraid, Sucraid |
| Genzyme Corporation | $225.71 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $218.28 | 2019-2025 | Ocaliva |
| Braintree Laboratories, INC. | $215.60 | 2021-2025 | Sutab, Suflave |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $197.37 | 2019-2025 | Injectafer |
| Allergan, INC. | $147.05 | 2019-2020 | |
| Celltrion USA INC. | $142.96 | 2024-2025 | Zymfentra, Vegzelma |
| Ferring Pharmaceuticals INC. | $139.50 | 2019-2025 | Rebyota, Clenpiq |
| E.R. Squibb & Sons, L.L.C. | $133.83 | 2021-2023 | Zeposia |
| Medtronic, INC. | $133.23 | 2023-2025 | Interstim |
| Lucid Diagnostics INC. | $130.93 | 2024 | |
| Nestle Healthcare Nutrition INC. | $127.79 | 2021-2023 | |
| Ardelyx, INC. | $125.14 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $122.25 | 2019 | |
| Endogastric Solutions, INC | $116.09 | 2022 | |
| Redhill Biopharma INC. | $112.51 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Aimmune Therapeutics, INC. | $100.54 | 2024-2025 | Vowst, Zenpep |
| Gilead Sciences, INC. | $89.28 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $74.79 | 2025 | Dupixent |
| Fresenius Kabi USA, LLC | $71.64 | 2023 | Idacio |
| Shionogi INC | $66.77 | 2019 | |
| Novo Nordisk INC | $63.51 | 2023-2025 | Wegovy, Saxenda |
| Biocon Biologics INC | $60.95 | 2024-2025 | Hulio, Yesintek |
| Neuraxis, INC. | $46.43 | 2025 | |
| Shire North American Group INC | $34.96 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.79 | 2025 | Iqirvo |
| Amgen INC. | $20.50 | 2023 | Avsola, Amjevita |
| Ucb, INC. | $17.30 | 2019 | |
| Rayner Intraocular Lenses Limited | $17.16 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Boston Scientific Corporation | $16.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Floyd Angus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.